Anterogen.Co.,Ltd. (065660.KQ)
KRW 16060.0
(-6.3%)
KRW 16060.0
(-6.3%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -437.82 Million KRW | -89.24% |
| 2022 | -4.39 Billion KRW | -70.82% |
| 2021 | 1.62 Billion KRW | 31.63% |
| 2020 | -3.5 Billion KRW | -65.74% |
| 2019 | -2.35 Billion KRW | -10.45% |
| 2018 | 1.25 Billion KRW | -289.64% |
| 2017 | 898.64 Million KRW | 20.11% |
| 2016 | 682.5 Million KRW | 167.84% |
| 2015 | 171.22 Million KRW | 112.94% |
| 2014 | -1.32 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -767.29 Million KRW | -259.32% |
| 2024 Q1 | -843.87 Million KRW | -140.24% |
| 2023 Q4 | -327.26 Million KRW | 58.56% |
| 2023 Q3 | -789.63 Million KRW | 53.83% |
| 2023 Q2 | -1.71 Billion KRW | -1745.85% |
| 2023 FY | - KRW | -89.24% |
| 2023 Q1 | -92.64 Million KRW | 83.79% |
| 2022 Q2 | -778.92 Million KRW | -167.45% |
| 2022 Q1 | -291.24 Million KRW | -19.29% |
| 2022 Q4 | -571.49 Million KRW | 3.42% |
| 2022 Q3 | -591.75 Million KRW | 24.03% |
| 2022 FY | - KRW | -70.82% |
| 2021 Q3 | -586.16 Million KRW | -856.4% |
| 2021 Q2 | -61.28 Million KRW | 85.26% |
| 2021 Q4 | -244.14 Million KRW | 58.35% |
| 2021 FY | - KRW | 31.63% |
| 2021 Q1 | -415.87 Million KRW | 57.72% |
| 2020 Q4 | -983.65 Million KRW | -135.99% |
| 2020 Q3 | -416.82 Million KRW | 54.42% |
| 2020 Q2 | -914.49 Million KRW | -13.86% |
| 2020 Q1 | -803.18 Million KRW | 19.66% |
| 2020 FY | - KRW | -65.74% |
| 2019 FY | - KRW | -10.45% |
| 2019 Q4 | -999.75 Million KRW | -70.77% |
| 2019 Q3 | -585.44 Million KRW | -8.68% |
| 2019 Q2 | -538.7 Million KRW | -59.92% |
| 2019 Q1 | -336.86 Million KRW | 48.83% |
| 2018 Q3 | -483.85 Million KRW | -190.69% |
| 2018 Q4 | -658.27 Million KRW | -36.05% |
| 2018 Q1 | -28.61 Million KRW | -636.13% |
| 2018 Q2 | -166.45 Million KRW | -481.69% |
| 2018 FY | - KRW | -289.64% |
| 2017 Q1 | 707.78 Million KRW | 239.38% |
| 2017 Q3 | 329.65 Million KRW | 183.65% |
| 2017 Q2 | -394.09 Million KRW | -155.68% |
| 2017 Q4 | 5.33 Million KRW | -98.38% |
| 2017 FY | - KRW | 20.11% |
| 2016 Q3 | 160.21 Million KRW | 143.0% |
| 2016 Q4 | -507.81 Million KRW | -416.96% |
| 2016 Q2 | -372.6 Million KRW | -132.3% |
| 2016 Q1 | 1.15 Billion KRW | 1400.84% |
| 2016 FY | - KRW | 167.84% |
| 2015 Q2 | -284.77 Million KRW | -30.94% |
| 2015 FY | - KRW | 112.94% |
| 2015 Q3 | 596.62 Million KRW | 309.51% |
| 2015 Q4 | 76.85 Million KRW | -87.12% |
| 2015 Q1 | -217.48 Million KRW | 0.0% |
| 2014 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 99.746% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | 92.978% |
| BINEX Co., Ltd. | 10.87 Billion KRW | 104.027% |
| Bioneer Corporation | 10.04 Billion KRW | 104.359% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | 97.742% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 98.977% |
| Helixmith Co., Ltd | -53 Billion KRW | 99.174% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 100.625% |
| Medy-Tox Inc. | 32.69 Billion KRW | 101.339% |
| Peptron, Inc. | -12.65 Billion KRW | 96.539% |
| Amicogen, Inc. | 13.95 Billion KRW | 103.138% |
| Genexine, Inc. | -40.87 Billion KRW | 98.929% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | 105.32% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 99.387% |
| ALTEOGEN Inc. | 440.04 Million KRW | 199.496% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 100.42% |
| SillaJen, Inc. | -17.35 Billion KRW | 97.477% |
| JETEMA, Co., Ltd. | 11 Billion KRW | 103.977% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | 96.068% |
| Genomictree Inc. | -6.33 Billion KRW | 93.085% |
| MedPacto, Inc. | -32.6 Billion KRW | 98.657% |
| D&D Pharmatech | -9.05 Billion KRW | 95.166% |
| EASY BIO,Inc. | 24.32 Billion KRW | 101.8% |
| GI Innovation, Inc. | -51.33 Billion KRW | 99.147% |